Nicotinamide riboside — commonly referred to as NR — has become one of the most intensively studied NAD+ precursors in longevity and functional nutrition science. As a form of vitamin B3, NR is converted in the body to nicotinamide adenine dinucleotide (NAD+), a coenzyme central to energy metabolism, DNA repair, mitochondrial function, and cellular aging. With NAD+ levels known to decline significantly with age, NR supplementation has attracted substantial clinical attention across multiple disease areas. This article reviews the current state of NR research, the most active investigation directions, and what the evidence means for formulators and supplement brands.
What Is NR and Why Does NAD+ Matter
NAD+ is not simply a vitamin. It functions as an essential cofactor in hundreds of enzymatic reactions — from the electron transport chain that powers mitochondria, to sirtuin activation that regulates gene expression, to PARP enzymes involved in DNA damage repair. The problem is that human NAD+ levels decline by an estimated 50% between early adulthood and age 60, a trajectory strongly associated with the metabolic and neurological changes of aging.
NR reaches NAD+ through the salvage pathway — one of three biosynthetic routes alongside the Preiss-Handler pathway (from nicotinic acid) and the de novo pathway (from tryptophan). What distinguishes NR from other precursors is its ability to cross biological barriers and raise NAD+ in tissues, including — critically — the human brain.
Research Direction 1: Brain NAD+ Elevation and Cognitive Health
A 2024 study published in Magnetic Resonance in Medicine used 7 Tesla MRI scanning to measure cerebral NAD+ levels in healthy volunteers before and after a single 900mg oral dose of NR. Supplementation significantly increased mean brain NAD+ concentration from 0.392 to 0.458 mM — a measurable, in vivo increase confirmed by high-field spectroscopy. This finding was significant because it provided direct human brain evidence, not just blood biomarker data, that NR can cross into the central nervous system and elevate NAD+ where cognitive function depends on it.
A placebo-controlled trial in older adults with mild cognitive impairment found that NR supplementation at up to 1g/day significantly increased blood NAD+ levels, was well tolerated, and was associated with a modest increase in DNA methylation and a reduction in epigenetic age as measured by PhenoAge and GrimAge clocks — suggesting a potential impact on biological aging beyond energy metabolism alone.
The cognitive research frontier is now focused on Alzheimer’s disease risk, with trials examining NR’s effects on amyloid and tau biomarkers in adults with subjective cognitive decline — an area where 2025 data is actively emerging.
Research Direction 2: Long-COVID, Fatigue, and Mitochondrial Recovery
A 24-week randomized controlled trial conducted at Massachusetts General Hospital and published in eClinicalMedicine in November 2025 tested high-dose NR (2000mg/day) in 58 participants with long-COVID symptoms. Participants taking NR experienced increases in NAD+ levels and showed encouraging improvements in fatigue, sleep quality, and mood — pointing toward a possible therapeutic path for easing certain long-COVID symptoms.
The mechanism is well-grounded: long-COVID is characterized by mitochondrial dysfunction, immune dysregulation, and elevated inflammatory markers — all areas where NAD+ metabolism plays a regulatory role. This represents one of the most clinically active NR research directions in 2025, with real-world implications for formulations targeting post-viral recovery and chronic fatigue.
Research Direction 3: Muscle Function, Sarcopenia, and Physical Performance
Age-related muscle loss — sarcopenia — is one of the most consequential aspects of biological aging, affecting mobility, metabolic health, and independence. NR’s role in mitochondrial biogenesis has made it a candidate ingredient for muscle preservation research.
A 2025 systematic review and meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle concluded that current evidence does not yet support broad NR supplementation for preserving muscle mass and function in adults over 60, while noting that participants with severe mitochondrial dysfunction — such as those with mitochondrial myopathies — may show more pronounced benefits. The review identified supplementation dosage and baseline NAD+ deficiency as key variables requiring further investigation.
This nuanced finding is important for formulators: the strongest NR muscle evidence exists in metabolically compromised populations, suggesting targeted positioning over broad-market sports nutrition claims.
Research Direction 4: Neuroprotection and Neuroinflammation
Beyond cognition, NR is being studied for its potential in neuroprotective contexts including Parkinson’s disease, where the NADPARK trial demonstrated increased cerebral NAD+ metabolism following supplementation, and in acute neurological injury. Research published in Molecular Neurobiology in 2025 demonstrated that NR restored NAD+ levels and reduced oxidative stress and neuroinflammation in experimental brain injury models — extending the mechanistic case for NR’s role in central nervous system resilience.
NR vs. NMN: The Ongoing Precursor Debate
A question consistently raised in B2B supplement formulation discussions is whether NR or NMN represents the superior NAD+ precursor. Both enter the salvage pathway, but at different points: NMN must be converted to NR extracellularly before cellular uptake in most tissues, while NR enters cells directly via nucleoside transporters. Current human data supports both as effective NAD+ elevators, with the differentiating factors being bioavailability, cost, and formulation stability rather than fundamental mechanism. For clean-label, cost-effective NAD+ supplementation, NR remains the more extensively studied option with the deeper clinical evidence base as of 2025.
What This Means for Supplement Formulators and OEM Brands
The NR research landscape in 2025 points to four commercially viable positioning frameworks: cognitive health and healthy aging for adults over 40; post-viral recovery and energy metabolism; mitochondrial support for individuals with metabolic compromise; and longevity and epigenetic age management for the growing premium wellness segment.
For brands targeting the US and EU markets, NR is a well-established ingredient with a clean regulatory profile, strong consumer awareness, and an expanding clinical evidence base that continues to generate search traffic and media coverage. As a raw material, NR powder offers flexible formulation across capsules, tablets, and functional beverages — with no taste or solubility barriers.
NuCoreBio supplies pharmaceutical-grade NR and NAD+ precursor ingredients with full GMP, ISO 22000, and HACCP certification, HPLC batch verification, and complete documentation for US and EU regulatory submissions. OEM and ODM services are available from MOQ 500 units with a 10-day concept-to-delivery turnaround.
Request a free sample or B2B pricing inquiry to explore NR formulation options for your brand.